Your browser doesn't support javascript.
loading
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger, Julius; Liu, Yang; Xu, Simin; Chang, Silvia; Martin, Ross; Manhas, Savrina; Aeschbacher, Thomas; Han, Bin; Yazdi, Tahmineh; May, Lindsey; Han, Dong; Shornikov, Alex; Flaherty, John; Manuilov, Dmitry; Suri, Vithika; Asselah, Tarik; Lampertico, Pietro; Wedemeyer, Heiner; Aleman, Soo; Richards, Christopher; Mateo, Roberto; Maiorova, Evguenia; Cihlar, Tomas; Mo, Hongmei; Urban, Stephan.
Afiliação
  • Hollnberger J; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Center for Infection Research (DZIF), Heidelberg Partner Site, Heidelberg, Germany.
  • Liu Y; Gilead Sciences Inc., Foster City, California, USA. Electronic address: Yang.liu@gilead.com.
  • Xu S; Gilead Sciences Inc., Foster City, California, USA.
  • Chang S; Gilead Sciences Inc., Foster City, California, USA.
  • Martin R; Gilead Sciences Inc., Foster City, California, USA.
  • Manhas S; Gilead Sciences Inc., Foster City, California, USA.
  • Aeschbacher T; Gilead Sciences Inc., Foster City, California, USA.
  • Han B; Gilead Sciences Inc., Foster City, California, USA.
  • Yazdi T; Gilead Sciences Inc., Foster City, California, USA.
  • May L; Gilead Sciences Inc., Foster City, California, USA.
  • Han D; Gilead Sciences Inc., Foster City, California, USA.
  • Shornikov A; Gilead Sciences Inc., Foster City, California, USA.
  • Flaherty J; Gilead Sciences Inc., Foster City, California, USA.
  • Manuilov D; Gilead Sciences Inc., Foster City, California, USA.
  • Suri V; Gilead Sciences Inc., Foster City, California, USA.
  • Asselah T; Department of Hepatologi, Hôpital Beaujon, AP-HP, Université de Paris-Cité, INSERM UMR 1149, Clichy, France.
  • Lampertico P; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy; "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Università degli Studi di Milano, Milan, Italy.
  • Wedemeyer H; Medizinische Hochschule, Hannover, Germany.
  • Aleman S; Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden.
  • Richards C; Gilead Sciences Inc., Foster City, California, USA.
  • Mateo R; Gilead Sciences Inc., Foster City, California, USA.
  • Maiorova E; Gilead Sciences Inc., Foster City, California, USA.
  • Cihlar T; Gilead Sciences Inc., Foster City, California, USA.
  • Mo H; Gilead Sciences Inc., Foster City, California, USA.
  • Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Center for Infection Research (DZIF), Heidelberg Partner Site, Heidelberg, Germany. Electronic address: Stephan.Urban@med.uni-heidelberg.de.
J Hepatol ; 79(3): 657-665, 2023 09.
Article em En | MEDLINE | ID: mdl-37120031
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Vírus Delta da Hepatite Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Vírus Delta da Hepatite Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha